Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector
Our guests examine the financial landscape for the cell and gene therapy (CGT) sector, providing an update that reflects opportunities and challenges.
Reni Benjamin, Managing Director, Healthcare Equity Research at Citizens
Brock Reeve, CEO and Co-founder, Eos BioInnovation
***
In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks with Reni Benjamin and Brock Reeve about the current financial landscape for cell and gene therapies (CGTs). They explore the unique dynamics companies face, from securing funding to navigating regulatory hurdles, and discuss how investors assess risks and opportunities in the field. While recent headlines suggest industry struggles, our guests provide a deeper look at what these headlines really mean for the sector’s future.
The interview covers the promising developments that the field continues to see , including positive clinical trial results and major acquisitions that signal stronger investor interest. Reni and Brock discuss how pricing strategies, market access and reimbursement models shape the financial outlook for CGT companies. They also highlight key trends that could influence the industry’s next phase of growth. As the conversation unfolds, they share their perspectives on what excites them most about the future of regenerative medicine.
Whether you’re an investor, industry professional, or simply curious about the business side of CGT, this episode offers valuable insights into the evolving financial landscape of this innovative sector.
